0000905148-25-003655.txt : 20251023 0000905148-25-003655.hdr.sgml : 20251023 20251023172623 ACCESSION NUMBER: 0000905148-25-003655 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251023 DATE AS OF CHANGE: 20251023 EFFECTIVENESS DATE: 20251023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RECODE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001693764 ORGANIZATION NAME: EIN: 811900562 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-561915 FILM NUMBER: 251413862 BUSINESS ADDRESS: STREET 1: 1140 O'BRIEN DR CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: (408) 585-1700 MAIL ADDRESS: STREET 1: 1140 O'BRIEN DR CITY: MENLO PARK STATE: CA ZIP: 94025 D 1 primary_doc.xml X0708 D LIVE 0001693764 RECODE THERAPEUTICS, INC. 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 408-585-1700 DELAWARE None None Corporation true Shehnaaz Suliman 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Executive Officer Director Peter A. Thompson 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Helen S. Kim 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Edward Hurwitz 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Rana Al-Hallaq 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Rakhshita Dhar 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Alan Colowick 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Patricia Millican 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Dean Mitchell 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Inai Park 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director Basheer Zada 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Director David Lockhart 1140 O'Brien Drive Menlo Park CA CALIFORNIA 94025 Executive Officer Biotechnology Decline to Disclose 06b false 2025-09-23 false true false 0 29441931 29441931 0 false 26 0 0 0 false RECODE THERAPEUTICS, INC. Max Barker Max Barker General Counsel of the Issuer 2025-10-23